Crossmark

Can personalized optimization of acid suppression dosage and duration improve the management of artificial ulcers after gastric endoscopic submucosal dissection?

Crossref DOI link: https://doi.org/10.1007/s00535-025-02227-x

Published Online: 2025-02-09

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ihara, Eikichi https://orcid.org/0000-0002-7070-6610
Hata, Yoshitaka

Ogino, Haruei
License Information

Text and Data Mining valid from 2025-02-09

Version of Record valid from 2025-02-09
More Information

Article History

Received: 17 January 2025

Accepted: 4 February 2025

First Online: 9 February 2025

Declarations

:

: H. Ogino belongs to an endowed course supported by Miyarisan Pharmaceutical Co., Ltd., Fujifilm Medical Co., Ltd., Terumo Corporation, FANCL Corporation, and Seiwa Medical Corporation. E. Ihara received lecture fees from Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Viatris Inc.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below